- cafead Mar 02, 2022 at 10:52: PM
via The long wait for phase 3 data on Inovio Pharmaceuticals' COVID-19 vaccine just got longer. With DNA vaccine INO-4800 generating significantly lower antibodies against omicron than the original SARS-CoV-2, Inovio has paused enrollment and asked regulators to change the primary endpoint to prevention of severe disease.
article source
article source